Ovagen
Ovagen, marketed liver and gastrointestinal peptide bioregulator
Written by Aaron CuhaReviewed Sep 2026
Also known as: Ovagen peptide, EDL (claimed sequence), Glu-Asp-Leu (claimed sequence)
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Ovagen is sold as a liver and gut peptide. Here is the problem. Search the medical database for it and you get 34 papers, and not one of them is about this. They are about waste water, gall bladder surgery, and germ free birds. There is no science on this product at all. Even the ingredient list is a guess.
What people take it for
- Helping a tired or fatty liver.
- Gut problems like bloating and poor digestion.
- A general detox or cleanse.
- Anti aging, because it is sold next to peptides that claim it.
What the trials actually showed
Nothing was shown, because nothing was tested. No trial. No animal study. No cell study. Not one paper under this name. Vendors say the ingredient is three amino acids called EDL. That is not confirmed either. A 2023 paper listed 26 of these tiny peptides with real published ingredient lists, and this one is not on it. To be fair, some retail names here may be relabelled versions of products that do have research under another name. That link has never been printed anywhere, so you cannot borrow it.
What people report
Reports, not trial results
The good
- Some people report better digestion in the first month.
- Some report more energy, which is the most common claim for anything in this family.
- Capsules are easy to take and cheap.
The bad
- Most reports are vague. People say they feel better without pointing at anything.
- Side effects are unknown. No study in this family reports any safety data at all.
- You do not know what is in it. There is no published test of the contents.
- If your liver numbers are off, taking this instead of getting blood work is the real risk.
Where these come from: Vendor sites and peptide forums only. There are no trial reports to draw from, because no trial exists.
My bottom line
I will say this one straight. There is no evidence of any kind, under any name, for this product. If your liver is the worry, go get blood work and find out what is actually wrong.
An opinion, not a finding. I am a coach, not a doctor.
Overview
Sold as a liver and gut peptide bioregulator with the sequence Glu-Asp-Leu. A PubMed search for Ovagen returns 34 records, none of them about this product: they are wastewater engineering, laparoscopic surgery and germ-free poultry. There is no indexed peer-reviewed evidence for this compound under this name, and even the sequence attribution is unverified.
Ovagen appears in retail peptide bioregulator catalogues as a liver and gastrointestinal product, usually with the sequence EDL, Glu-Asp-Leu, attached to it. It is one of the Cytogen and Cytomax style trade names sold alongside better known members of the Khavinson family.
Searched directly against PubMed, the name returns nothing relevant. The 34 records that come back include a method for sterilising isolators to produce germ-free eggs, machine learning for wastewater treatment plants, and a randomised trial of a pulmonary recruitment manoeuvre after laparoscopic cholecystectomy. None of them concerns a peptide bioregulator. A search for a liver peptide with the Glu-Asp-Leu sequence returns a single 1989 Biochemistry paper on guinea pig liver transglutaminase terminal sequencing, which is unrelated chemistry.
This page exists because the product is sold and because saying so plainly is more useful than the confident mechanism write-ups that circulate for it. The organ-target claim, the sequence attribution and the dosing advice you will find on vendor pages are not traceable to any indexed source.
One qualification, and it cuts both ways. Several retail names in this family are probably marketing labels for polypeptide complexes that do have literature under a different name. That mapping is itself unverified. It is plausible that Ovagen corresponds to a liver polypeptide complex studied in Russian work under another name, and it is not established, so nothing published about any such complex can be attributed to this product.
Mechanism of action
No mechanism has been demonstrated for this product. The circulating account, that a Glu-Asp-Leu tripeptide enters hepatocytes and regulates transcription of liver-specific genes, is an extension of the general Khavinson epigenetic hypothesis applied to an organ label. A 2023 paper lists 26 biologically active ultrashort peptides with published sequences and models their transport; the sequences named there include ED, DS, DR, EDR, EDG, AEDR, AEDL, KEDP, KEDG and AEDG. EDL is not among them under this trade name, which is why the sequence attribution for Ovagen is reported here as unverified rather than as fact.
Reading the research record
The honest summary of this page is a negative search result, so the method matters. The name was searched against PubMed directly, returning 34 records that were individually checked by title and found to concern unrelated fields. A separate search for a liver peptide carrying the claimed Glu-Asp-Leu sequence returned one 1989 protein chemistry paper about guinea pig liver transglutaminase, also unrelated. ClinicalTrials.gov has no registered study of any compound in this family.
Ovagen belongs to a list of retail trade names that each returned nothing on individual search: Endoluten, Vladonix, Cerluten, Suprefort, Svetinorm, Ventfort, Zhenoluten, Glandokort, Pielotax, Stamakort, Bonothyrk, Taxorest, Visoluten, Gotratix, Honluten, Libidon, Normoftal, Bonomarlot, Thyreogen, Ventragen, Cerebramin, Chondramin, Testalamin and Ovariamin. Naming the whole list is more useful than treating each one as a separate mystery.
Everything in the Khavinson peptide bioregulator family shares one structural problem, and it is not a problem with the chemistry. Not one compound in the family has a registered clinical trial: ClinicalTrials.gov returns zero studies for epitalon, thymalin, cortexin, retinalamin, prostatilen and epithalamin alike, on a query shape that returns results for ordinary drugs. The literature sits almost entirely in three journals, Advances in Gerontology, Bulletin of Experimental Biology and Medicine and Vestnik Oftalmologii, most of it in Russian with English abstracts only, and most of it authored by the St. Petersburg Institute of Bioregulation and Gerontology or by Anisimov's group in the same city. No independent replication outside those groups has been located for any of the lifespan claims. Separately, no adverse event data appears in any of the abstracts retrieved for this family. The Russian literature in this area does not systematically report safety endpoints, and that absence should be read as missing data rather than as a clean safety record.
The evidence, charted
Fig. 1 · evidence composition
0of 3 citations (0%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 1998 and 2023.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- In vitro2023
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters.
The reference list of ultrashort peptides with documented sequences from this research group. ED, DS, DR, EDR, EDG, AEDR, AEDL, KEDP, KEDG and AEDG are named. This is the paper you would expect an EDL liver peptide to appear in, and it does not appear under the Ovagen name, which is the basis for calling the sequence attribution unverified.
Biomolecules - Review2023
[Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation.].
Included as an example of what a peptide bioregulator page looks like when the compound does have published work: a named peptide, a named complex, a stated model and a stated claim. Nothing equivalent exists for Ovagen. Cited here to show the contrast, not because it studied this product.
Advances in Gerontology - Animal1998
Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats.
The best-documented animal result in the whole bioregulator family, for a different organ preparation entirely. Mean lifespan rose 11 to 31 percent in female Drosophila, SHR mice, C3H/Sn mice and LIO rats. It is cited on this page as the class benchmark: this is what a bioregulator result looks like when one exists, and Ovagen has nothing comparable.
Mechanisms of Ageing and Development
Frequently asked questions
Is there any study of Ovagen?
No. Not one indexed peer-reviewed paper concerns this product. The records that come back on a search are about wastewater treatment, abdominal surgery and germ-free birds.
Does Ovagen repair the liver?
Nothing has been measured. No liver enzyme, no biopsy, no imaging, no outcome, in any species, under this name. The liver claim is a product category, not a finding.
Is the sequence really Glu-Asp-Leu?
Vendors say so. It is not confirmed in any indexed source, including the 2023 paper that catalogues 26 ultrashort peptide sequences from this same research programme. Treat the sequence as a marketing attribution.
Could Ovagen be a real complex sold under a different name?
Possibly. Several retail names in this family are probably labels for polypeptide complexes that do have Russian literature under other names. That mapping has never been published, so you cannot borrow another compound's data for this bottle.
Why publish a page for something with no evidence?
Because the product is sold, people search for it, and the pages they find invent a mechanism. Stating that the record is empty is the finding.